慈姑平岩方对lumina1A型乳腺癌内分泌治疗患者的疗效及预后分析

Analysis on the Effect and the Prognosis of Cigu Pingyan Formula for the Patients with Endocrine Therapy of Lumina1 A Type Breast Cancer

目的:观察慈姑平岩方对lumina1A型乳腺癌内分泌治疗患者的疗效及预后的影响。方法:选取2015年1月至2019年1月在我院治疗的Luminal A型乳腺癌患者120例,根据治疗方案分为观察组(n=58)和对照组(n=62),对照组给予内分泌治疗,观察组在对照组基础上给予慈姑平岩方,观察两组治疗疗效、无进展生存时间等,检测治疗前后血清促黄体生成素(LH)、卵泡刺激素(FSH)、雌二醇(E2)、癌胚抗原(CEA)和糖蛋白抗原125(CA125)水平。结果:观察组治疗疗效优于对照组(P<0.05),其治疗总有效率为68.97%;观察组和对照组治疗前后FSH、E2比较差异无统计学意义(P<0.05);观察组治疗后1个月LH为(10.45±1.35)IU/L,明显低于对照组(P<0.05);观察组治疗后1个月CEA、CA125分别为(2.24±0.87)ng/ml和(14.57±2.97U/ml),明显低于对照组(P<0.05);观察组无疾病进展时间为54个月(95%CI:53.21~54.79),与对照组比较差异无统计学意义(P<0.05);观察组和对照组不良反应发生率比较差异无统计学意义(P>0.05)。结论:慈姑平岩方联合内分泌治疗lumina1A型乳腺癌有较好的效果,值得临床使用。

Objective:To explore the effect of and prognosis of Cigu Pingyan Formula for patients with endocrine therapy of luminal A type breast cancer.Methods:From January 2015 to January 2019,120 patients with luminal type A breast cancer were selected,according to the treatment plan,the patients were divided into observation group(n=58)and controlled group(n=62),the controlled group was given endocrine therapy,and the observation group was given Cigu Pingyan Formula on the basis of the controlled group,the therapeutic effect and progression free survival time of the two groups were observed,the serum luteinizing hormone(LH),follicle stimulating hormone(FSH),estradiol(E2),carcinoembryonic antigen(CEA)and glycoprotein antigen 125(CA125)were measured before and after treatment.Results:The therapeutic effect of the observation group was better than that of the controlled group(P<0.05),and the total effective rate was 68.97%.There was no significant difference in FSH and E2 between the observation group and the controlled group before and after treatment(P<0.05).One month after treatment,LH in the observation group was(10.45±1.35)IU/L,which was significantly lower than that in the controlled group(P<0.05).One month after treatment,CEA and CA125 in the observation group were(2.24±0.87)ng/ml and(14.57±2.97 U/ml),which were significantly lower than those in the controlled group(P<0.05).The time without disease progression in the observation group was 54 months(95%CI:53.21~54.79),with no statistically significant difference from the controlled group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the observation group and the controlled group(P>0.05).Conclusion:Cigu Pingyan Formula combined with endocrine therapy has a good effect on luminal A type breast cancer,which is worthy of clinical use.